The Latest Breaking News on Pharma

Federal officials have cleared the way for Florida to begin importing cheaper prescription drugs from Canada

KYMR stock rocketed and then toppled Friday after Kymera outlined its newest immune disease drugs and tacked on a $275 million offering.

The pharmaceutical industry’s robust outlook is driven by high healthcare spending globally, consistent R&D efforts, and the rapid adoption of advanced digital technologies. So, let’s analyze if investors should adopt a bullish or bearish stance on pharma stocks such as Tilray Brands (TLRY), CytomX Therapeutics (CTMX), and Wave Life Sciences…

Consulting firm McKinsey and Co. has agreed to pay $78 million to settle claims from insurers and health care funds that its marketing work with Purdue Pharma helped fuel an opioid addiction crisis

CymaBay is sprinting to the finish line with a treatment for a serious liver disease and CBAY stock is on a massive run.

Hospitals rely on scores of generic drugs given by injection. But these workhorses are often in short supply. Cheap prices have led to factory closures that leave the supply chain vulnerable.

Growing healthcare spending and the use of cutting-edge technologies in the research and development of new drugs have put the pharmaceutical industry in a strong position for growth. With such constructive trends in mind, it's wise to buy fundamentally strong pharma stocks, Merck (MRK), Collegium (COLL) and Johnson & Johnson…

Warning that drugs so potent a ‘grain of sand’ dosage can be fatal could spark a US-style drug deaths crisis

Amid rising global medical needs, the pharmaceutical industry is expected to witness robust growth in the coming years. Given the solid long-term prospects of the industry, fundamentally sound pharma stocks Spero Therapeutics (SPRO), Astellas Pharma (ALPMY) and Supernus Pharmaceuticals (SUPN) could be ideal buys for steady gains. Read on.